Clinical Trials on Chronic Myelogous Leukemia/Other Leukemia

Total 7741 results

University of Bonn
Pfizer; RWTH Aachen University; Ludwig-Maximilians - University of Munich; Heidelberg... and other collaborators

Unknown

Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients (BODO)

Chronic Myelogenous Leukaemia

Germany
Versailles Hospital

Recruiting

PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS (PONAZA)

CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE | CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS

France
University of Liverpool
Imperial College London; Newcastle University; University of Glasgow

Unknown

De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia (DESTINY)

Chronic Myeloid Leukaemia

United Kingdom
PETHEMA Foundation

Completed

Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia

Chronic Myeloid Leukaemia

Spain
Samara State Medical University

Recruiting

Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib

Chronic Myeloid Leukaemia

Russian Federation
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib (CML0609)

Chronic Myeloid Leukaemia

Italy
Australasian Leukaemia and Lymphoma Group
Merck Sharp & Dohme LLC; Novartis Pharmaceuticals

Unknown

Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia (PInNACLe)

Chronic Myeloid Leukaemia

Australia
University Hospital, Bordeaux

Completed

Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib (STIM 2)

Chronic Myeloid Leukaemia

France
University College, London
Bloodwise

Active, not recruiting

Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers (UK-Haplo)

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Myelodysplastic Syndrome | Acute Myeloid Leukaemia | Chronic Lymphocytic Leukaemia | Acute Lymphoblastic Leukaemia | Chronic Myeloid Leukaemia | Acquired Bone Marrow Failure Syndromes | Other Haematological Malignancies; Unrelated HSCT Indicated

United Kingdom
Cell Medica Ltd
University College, London; Cell Therapy Catapult

Completed

WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study

Acute Myeloid Leukaemia | Chronic Myeloid Leukaemia

United Kingdom
National Cancer Institute (NCI)

Completed

Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Novartis Pharmaceuticals

Terminated

Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. (ENESTswift)

Philidelphia Positive Chronic Myeloid Leukaemia

Australia
National Cancer Institute (NCI)

Terminated

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Grupo Cooperativo de Hemopatías Malignas

Recruiting

Myeloid Mutations Register in R/R CML

Chronic Myeloid Leukaemia Recurrent | Chronic Myeloid Leukemia, in Relapse

Mexico
National Cancer Institute (NCI)

Terminated

Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Completed

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Completed

Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase (CML0912)

Chronic Phase Philadelphia Positive | BCR-ABL Positive | Chronic Myeloid Leukaemia

Italy
M.D. Anderson Cancer Center
Novartis

Completed

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

Leukemia, Myelogenous, Chronic

United States
The University of Hong Kong

Unknown

Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia

Leukemia, Myelogenous, Chronic Phase

Hong Kong
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
Hoffmann-La Roche

Completed

An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies

Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute

United States, France, Canada
University of California, San Francisco
American Society of Hematology

Completed

A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors

Chronic Myeloid Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Myeloproliferative Neoplasm

United States
Assiut University

Unknown

Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor

Chronic Phase Chronic Myelogenous Leukemia
Hospices Civils de Lyon

Completed

Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia (NILOPEG)

Chronic Myelogenous Leukemia

France
Pfizer

Completed

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Chronic Myeloid Leukaemia

Hungary
Pfizer
pH Associates

Completed

A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands

Chronic Myeloid Leukaemia

United Kingdom
Novartis Pharmaceuticals

Completed

Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia

Chronic Myeloid Leukaemia

United Kingdom
Medical College of Wisconsin
H. Jean Khoury Cure CML Consortium

Recruiting

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Chronic Phase Chronic Myelogenous Leukemia

United States
Thomas Jefferson University

Completed

A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia

Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Incyte Biosciences UK

Completed

CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | Blastic Phase Chronic Myelogenous Leukemia

United Kingdom, Ireland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment

Leukemia
M.D. Anderson Cancer Center

Completed

Late Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States
Kanto CML Study Group

Unknown

Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

Myelogenous Leukemia, Chronic, Chronic Phase

Japan
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Unspecified Childhood Solid Tumor, Protocol Specific | Accelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic... and other conditions

United States
M.D. Anderson Cancer Center
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Myeloid, Chronic

United States
Children's Oncology Group
Pfizer; Erasmus Medical Center; Dutch Childhood Oncology Group; Innovative Therapies...

Active, not recruiting

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Blastic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive CML

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Immunex Corporation

Withdrawn

Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes

Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia
Bristol-Myers Squibb

Completed

Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia

Chronic Myelogenous Leukemia

Netherlands, United States, Italy, Argentina, Brazil, Canada, Germany, Peru, Singapore, Taiwan, United Kingdom, France, Korea, Republic of, Philippines, Sweden, Thailand, Finland, Australia, Israel, Belgium, Denmark, Norway, Switzer...
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia

Accelerated Phase Chronic Myelogenous Leukemia (CML) | Blast Phase Chronic Myelogenous Leukemia (CML) | Chronic Phase Phase Chronic Myelogenous Leukemia (CML) | Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)

United States
Pfizer

Completed

Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Chronic Myelogenous

Japan
Heidelberg University

Completed

Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia

Germany, Switzerland
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Leukemia

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Novartis Pharmaceuticals

Completed

Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate

Leukemia

United States
Pfizer

Completed

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

France, United States, Canada, Spain, Czechia, Singapore, Thailand, Denmark, Norway, Korea, Republic of, Finland, Hungary, Sweden, Netherlands, Italy, Germany, Ukraine, South Africa, Taiwan, Australia, Belgium, Israel, Mexico, Poland, S... and more
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

Accelerated Phase Chronic Myelogenous Leukemia | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb

Completed

BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate

Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States

Clinical Trials on Chronic Myelogous Leukemia/Other Leukemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations